Amgen discovers, develops, manufactures, and distributes human therapeutics across multiple therapeutic areas including immunology, oncology, cardiovascular disease, bone health, and nephrology. The company's primary revenue drivers include Enbrel for rheumatoid arthritis and psoriatic conditions, Prolia and Evenity for osteoporosis, Repatha for cardiovascular risk reduction, and several oncology products including Kyprolis for multiple myeloma and Blincyto for acute lymphoblastic leukemia. Recent product additions such as Tezspire for asthma and Lumakras for lung cancer expand its portfolio across different disease states.
The company operates through strategic partnerships to broaden its therapeutic reach. Notable collaborations include agreements with AstraZeneca for Tezspire development, UCB for Evenity commercialization, and BeiGene for oncology product expansion. Amgen distributes its products primarily through pharmaceutical wholesale distributors to healthcare providers, including physicians, clinics, dialysis centers, hospitals, and pharmacies.
Headquartered in Thousand Oaks, California, Amgen operates at significant scale with approximately 31,500 full-time employees. The company maintains a global commercial presence supporting its worldwide therapeutic distribution network across multiple markets and geographic regions.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $14.23 | $14.33 | +88.2% | |
| 2024 | $7.56 | $7.62 | -39.5% | |
| 2023 | $12.49 | $12.56 | +3.1% | |
| 2022 | $12.11 | $12.18 | +17.8% | |
| 2021 | $10.28 | $10.34 | +272.5% | |
| 2020 | $2.76 | $2.78 | -3.2% | |
| 2019 | $2.85 | $2.87 | -5.3% | |
| 2018 | $3.01 | $3.04 | +151.1% | |
| 2017 | $-5.89 | $-5.89 | -327.4% | |
| 2016 | $2.59 | $2.61 | +9.3% | |
| 2015 | $2.37 | $2.39 | +41.1% | |
| 2014 | $1.68 | $1.70 | +26.3% | |
| 2013 | $1.33 | $1.35 | +31.7% | |
| 2012 | $1.01 | $1.03 | -6.5% | |
| 2011 | $1.08 | $1.09 | +0.0% | |
| 2010 | $1.08 | $1.09 | -76.1% | |
| 2009 | $4.51 | $4.53 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-13 | 0000318154-26-000010 | SEC ↗ |
| 2024-12-31 | 2025-02-14 | 0000318154-25-000010 | SEC ↗ |
| 2023-12-31 | 2024-02-14 | 0000318154-24-000011 | SEC ↗ |
| 2022-12-31 | 2023-02-09 | 0000318154-23-000017 | SEC ↗ |
| 2021-12-31 | 2022-02-16 | 0000318154-22-000010 | SEC ↗ |
| 2020-12-31 | 2021-02-09 | 0000318154-21-000010 | SEC ↗ |
| 2019-12-31 | 2020-02-12 | 0000318154-20-000017 | SEC ↗ |
| 2018-12-31 | 2019-02-13 | 0000318154-19-000008 | SEC ↗ |
| 2017-12-31 | 2018-02-13 | 0000318154-18-000004 | SEC ↗ |